Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
HU
TuHURA Biosciences, Inc. Common Stock
HURA
Mkt Cap
$112.5M
Volume
80.96K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
HU
HURA
HU
TuHURA Biosciences, Inc. Common Stock
HURA
News
·
Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight
Mkt Cap
$116.6M
Volume
80.96K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Insider
Filings
Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight
The Merkel cell carcinoma market is expected to grow significantly between 2025-2034, driven by rising global incidence, increased awareness, and innovative treatment developments like immunotherapies and targeted therapies.
GlobeNewswire Inc. · Aug 20, 2025
TuHURA R&D Jumps 75% in Q2
TuHURA Biosciences advanced its immuno-oncology pipeline in Q2 2025, launching a Phase 3 trial for IFx-2.0 in Merkel cell carcinoma and completing the Kineta acquisition. The company raised $15.5 million in equity financing to support ongoing clinical development.
The Motley Fool · Aug 15, 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders
Halper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales and mergers of The Shyft Group, MoneyLion Inc., TuHURA Biosciences, Inc., and Kineta, Inc.
Benzinga · Dec 19, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ML, PDCO, HURA, KANT on Behalf of Shareholders
Halper Sadeh LLC is investigating several companies, including MoneyLion Inc., Patterson Companies, Inc., TuHURA Biosciences, Inc., and Kineta, Inc., for potential violations of securities laws and breaches of fiduciary duties to shareholders related to proposed mergers and acquisitions.
GlobeNewswire Inc. · Dec 14, 2024
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT
The M&A Class Action Firm is investigating the proposed merger between Kineta, Inc. (OTC: KANT) and TuHURA Biosciences, Inc. The firm is looking into the terms of the agreement, where TuHURA would acquire the rights to Kineta's KVA12123 antibody.
Benzinga · Dec 12, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
HU
HURA
TuHURA Biosciences, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
HURA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any HURA yet.
Related Tickers
Earnings